金陵药业：噁拉戈利片获批开展Ⅲ期临床研究

Core Viewpoint - Jinling Pharmaceutical (000919) has received approval from the National Medical Products Administration for the clinical trial of Olaragoli tablets, which are intended for the treatment of moderate to severe pain associated with endometriosis [1] Company Summary - Jinling Pharmaceutical's subsidiary, Jinling Pharmaceutical Factory, has been granted a Clinical Trial Approval Notice for Olaragoli tablets [1] - The clinical research will be conducted in Phase III, indicating a significant step towards potential market introduction [1] Industry Summary - The approval of Olaragoli tablets highlights ongoing advancements in the pharmaceutical industry, particularly in addressing women's health issues such as endometriosis [1]